Difference between revisions of "Part:BBa K2666001"
| Line 1: | Line 1: | ||
| + | The Montpellier iGEM team 2018 designed a construction that produce LL-37, an antimicrobial peptide from human macrophages and leukocytes in Lactobacillus jensenii (more information). | ||
| + | For that, we used the promoter RpsU, a L.jensenii specific strong promoter [1]. This RpsU sequence also contains the putative sequence for the RBS. Figure 1 illustrates the detailed design. | ||
| + | |||
| + | Figure 1 : Construct design. The sequence that encode LL-37 with a strong promoter RpsU. | ||
| + | |||
| + | LL-37 has shown effect in vivo in mice. Females naturally cycling to estrous phase failed to become pregnant when in injected with LL-37 and sperm. LL-37 also showed in vitro effect on human sperm which makes it a very good potential peptide for contraception. [2] | ||
Revision as of 07:29, 10 October 2018
The Montpellier iGEM team 2018 designed a construction that produce LL-37, an antimicrobial peptide from human macrophages and leukocytes in Lactobacillus jensenii (more information). For that, we used the promoter RpsU, a L.jensenii specific strong promoter [1]. This RpsU sequence also contains the putative sequence for the RBS. Figure 1 illustrates the detailed design.
Figure 1 : Construct design. The sequence that encode LL-37 with a strong promoter RpsU.
LL-37 has shown effect in vivo in mice. Females naturally cycling to estrous phase failed to become pregnant when in injected with LL-37 and sperm. LL-37 also showed in vitro effect on human sperm which makes it a very good potential peptide for contraception. [2]